CCL3 and Behcet disease: The MIP-1α increase was significantly lower in the treated groups compared to the BD group: Coversin group 47 pg/mL (15–79) (p < 0.0001), anti-CD14 group 28 pg/mL (2.3–54) (p < 0.0001) and the dual treatment group 57 pg/mL (-12-126) (p < 0.0001) (Fig. 2B).